Q-omics provides the consensus-scored RPL35AP13 profile across patient tissues and cancer cell-line models. RPL35AP13 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL35AP13 is differentially expressed in 5, with the highest sampling consensus in READ. Additionally, RPL35AP13 RNA expression shows 12,915 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, READ, and GBM as cancer lineages where RPL35AP13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35AP13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35AP13 survival associations across molecular data types. RPL35AP13 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35AP13 RNA expression–survival associations across cancer types. High RPL35AP13 expression shows unfavorable associations in OV, SKCM, LGG, KICH and PAAD, but favorable associations in CHOL. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify OV as the clearest survival context for RPL35AP13 RNA expression.
This table summarizes RPL35AP13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL35AP13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35AP13 shows lower tumor expression in READ and THCA and higher tumor expression in COAD, HNSC and LUAD. The READ box plot shows higher RPL35AP13 RNA expression in normal versus tumor tissue (log2 FC = −0.229, t-test p = .001).
This table shows molecular features associated with RPL35AP13 in patient tissues and cancer cell lines. In patient samples, RPL35AP13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
